FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112679936> ?p ?o ?g. }

• W2112679936 endingPage "1593" @default.
• W2112679936 startingPage "1584" @default.
• W2112679936 abstract "Study objective In September 2000, the US Food and Drug Administration (FDA) approved the use of Flovent Diskus (FD) [fluticasone propionate; GlaxoSmithKline; Research Triangle Park, NC], which is an orally inhaled, dry-powder corticosteroid, for the maintenance treatment of asthma at dosages of 50 to 1,000 μg administered twice-daily. Once-daily dosage regimens did not receive approval. This article will detail six clinical trials, five of which incorporated comparative once-daily and twice-daily treatment arms of the same nominal dose of FD. Design Six 12-week, randomized, double-blind, placebo-controlled studies in patients with mild-to-moderate asthma, including two pediatric asthma trials (patient age, 4 to 11 years) of total daily doses of fluticasone propionate (FP) of 100 or 200 μg, and four adult and adolescent studies of total daily doses of FP of 100, 200, or 500 μg. Results Twice-daily dosing was numerically superior to once-daily dosing at the same nominal dose in all comparative studies for the primary end point, change in predose FEV1. In five trials, the results of the once-daily dosage of FP were statistically indistinguishable from those with placebo. One trial demonstrated the superiority of FP, 500 μg once-daily, over placebo; however, the effect size was half that observed with twice-daily dosing. Once-daily FP dosing showed no advantage in safety or in patient adherence to medication. Conclusions In the FDA review of once-daily dosing of the FD regimen, 100 or 200 μg once-daily dosing was not shown to be significantly better than placebo. FP 500 μg once-daily was found to be superior to placebo, but at about one half the effect size as the same nominal dose given bid. No advantage in patient safety or adherence was demonstrated for once-daily administration over twice-daily administration, and once-daily administration is not currently recommended. In September 2000, the US Food and Drug Administration (FDA) approved the use of Flovent Diskus (FD) [fluticasone propionate; GlaxoSmithKline; Research Triangle Park, NC], which is an orally inhaled, dry-powder corticosteroid, for the maintenance treatment of asthma at dosages of 50 to 1,000 μg administered twice-daily. Once-daily dosage regimens did not receive approval. This article will detail six clinical trials, five of which incorporated comparative once-daily and twice-daily treatment arms of the same nominal dose of FD. Six 12-week, randomized, double-blind, placebo-controlled studies in patients with mild-to-moderate asthma, including two pediatric asthma trials (patient age, 4 to 11 years) of total daily doses of fluticasone propionate (FP) of 100 or 200 μg, and four adult and adolescent studies of total daily doses of FP of 100, 200, or 500 μg. Twice-daily dosing was numerically superior to once-daily dosing at the same nominal dose in all comparative studies for the primary end point, change in predose FEV1. In five trials, the results of the once-daily dosage of FP were statistically indistinguishable from those with placebo. One trial demonstrated the superiority of FP, 500 μg once-daily, over placebo; however, the effect size was half that observed with twice-daily dosing. Once-daily FP dosing showed no advantage in safety or in patient adherence to medication. In the FDA review of once-daily dosing of the FD regimen, 100 or 200 μg once-daily dosing was not shown to be significantly better than placebo. FP 500 μg once-daily was found to be superior to placebo, but at about one half the effect size as the same nominal dose given bid. No advantage in patient safety or adherence was demonstrated for once-daily administration over twice-daily administration, and once-daily administration is not currently recommended." @default.
• W2112679936 created "2016-06-24" @default.
• W2112679936 creator A5003317478 @default.
• W2112679936 creator A5005198440 @default.
• W2112679936 creator A5005454624 @default.
• W2112679936 creator A5079380290 @default.
• W2112679936 date "2003-10-01" @default.
• W2112679936 modified "2023-10-12" @default.
• W2112679936 title "Inhaled Fluticasone Propionate by Diskus in the Treatment of Asthma" @default.
• W2112679936 cites W1987467897 @default.
• W2112679936 cites W2003292549 @default.
• W2112679936 cites W2057590635 @default.
• W2112679936 cites W2061819610 @default.
• W2112679936 cites W2075965686 @default.
• W2112679936 cites W2082466693 @default.
• W2112679936 cites W2106823205 @default.
• W2112679936 cites W2143835782 @default.
• W2112679936 cites W2163004350 @default.
• W2112679936 cites W2341674111 @default.
• W2112679936 doi "https://doi.org/10.1378/chest.124.4.1584" @default.
• W2112679936 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14555594" @default.
• W2112679936 hasPublicationYear "2003" @default.
• W2112679936 type Work @default.
• W2112679936 sameAs 2112679936 @default.
• W2112679936 citedByCount "34" @default.
• W2112679936 countsByYear W21126799362012 @default.
• W2112679936 countsByYear W21126799362019 @default.
• W2112679936 crossrefType "journal-article" @default.
• W2112679936 hasAuthorship W2112679936A5003317478 @default.
• W2112679936 hasAuthorship W2112679936A5005198440 @default.
• W2112679936 hasAuthorship W2112679936A5005454624 @default.
• W2112679936 hasAuthorship W2112679936A5079380290 @default.
• W2112679936 hasConcept C126322002 @default.
• W2112679936 hasConcept C142724271 @default.
• W2112679936 hasConcept C162156334 @default.
• W2112679936 hasConcept C204787440 @default.
• W2112679936 hasConcept C27081682 @default.
• W2112679936 hasConcept C2776042228 @default.
• W2112679936 hasConcept C2776804153 @default.
• W2112679936 hasConcept C2777288759 @default.
• W2112679936 hasConcept C2779028295 @default.
• W2112679936 hasConcept C2781212218 @default.
• W2112679936 hasConcept C2781413609 @default.
• W2112679936 hasConcept C42219234 @default.
• W2112679936 hasConcept C535046627 @default.
• W2112679936 hasConcept C71924100 @default.
• W2112679936 hasConceptScore W2112679936C126322002 @default.
• W2112679936 hasConceptScore W2112679936C142724271 @default.
• W2112679936 hasConceptScore W2112679936C162156334 @default.
• W2112679936 hasConceptScore W2112679936C204787440 @default.
• W2112679936 hasConceptScore W2112679936C27081682 @default.
• W2112679936 hasConceptScore W2112679936C2776042228 @default.
• W2112679936 hasConceptScore W2112679936C2776804153 @default.
• W2112679936 hasConceptScore W2112679936C2777288759 @default.
• W2112679936 hasConceptScore W2112679936C2779028295 @default.
• W2112679936 hasConceptScore W2112679936C2781212218 @default.
• W2112679936 hasConceptScore W2112679936C2781413609 @default.
• W2112679936 hasConceptScore W2112679936C42219234 @default.
• W2112679936 hasConceptScore W2112679936C535046627 @default.
• W2112679936 hasConceptScore W2112679936C71924100 @default.
• W2112679936 hasIssue "4" @default.
• W2112679936 hasLocation W21126799361 @default.
• W2112679936 hasLocation W21126799362 @default.
• W2112679936 hasOpenAccess W2112679936 @default.
• W2112679936 hasPrimaryLocation W21126799361 @default.
• W2112679936 hasRelatedWork W1975221239 @default.
• W2112679936 hasRelatedWork W1992988294 @default.
• W2112679936 hasRelatedWork W2020812663 @default.
• W2112679936 hasRelatedWork W2030829101 @default.
• W2112679936 hasRelatedWork W2040008754 @default.
• W2112679936 hasRelatedWork W2055935555 @default.
• W2112679936 hasRelatedWork W2160477136 @default.
• W2112679936 hasRelatedWork W2343833591 @default.
• W2112679936 hasRelatedWork W3030704863 @default.
• W2112679936 hasRelatedWork W4231997767 @default.
• W2112679936 hasVolume "124" @default.
• W2112679936 isParatext "false" @default.
• W2112679936 isRetracted "false" @default.
• W2112679936 magId "2112679936" @default.
• W2112679936 workType "article" @default.